Treatment with pegylated interferon and ribavirin in a patient with fibrosing cholestatic hepatitis due to recurrent hepatitis C after liver transplantation
Byung Kook Kim, M.D., So Young Kwon, M.D., Soon-Young Ko, M.D.,
Won Hyeok Choe, M.D., Chang Hong Lee, M.D., He-Seong Han, M.D.1,
Seong-Hwan Chang, M.D.2
Fibrosing cholestatic hepatitis (FCH) is the most devastating manifestation of recurrent hepatitis C in transplant recipients with hepatitis C virus (HCV), possibly leading to death or retransplantation. Although FCH was first described as a complication of hepatitis B, this manifestation has been well documented in association with HCV in the setting of liver transplantation, bone marrow transplantation, heart transplantation, and end-stage human immunodeficiency virus infection. We report the clinical course and antiviral response in a patient with FCH due to recurrent hepatitis C after cadaveric liver transplantation who was treated with pegylated interferon α-2a and ribavirin. (Korean J Hepatol 2008;14:519-524)
Folate-Polyethylene Glycol Conjugated Near-Infrared Fluorescence Probe with High Targeting Affinity and Sensitivity for In Vivo Early Tumor Diagnosis Fei Liu, Dawei Deng, Xinyang Chen, Zhiyu Qian, Samuel Achilefu, Yueqing Gu Molecular Imaging and Biology.2010; 12(6): 595. CrossRef
